123B9 

123B9, a tumor-homing agent, is a potent and selective EphA2 agonist with a K_d value of 4.0 μM. 123B9 selectively targets the EphA2 tyrosine kinase receptor ligand-binding domain. 123B9 does not appreciably inhibit the ligand binding domains of the most closely related EphA3 and EphA4 receptors^[1].

Kd: 4.0 μM (EphA2)^[1]

In mice, the mean plasma concentration over time following 123B9 IV administration (30 mg/kg) indicated that the compound is detectable in vivo at each time point tested (30 min, 1 hr, 2 hr, 4 hr) with a mean concentration in plasma of 447 ng/mL and 569 ng/mL still detectable at 2 hr and 4 hr, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1321.79

C₅₈H₈₂ClFN₁₂O₂₀

2225868-19-7

{2-(3-chloro-4-fluorophenoxy)acetic acid}-Ser-Ala-Tyr-Pro-Asp-Ser-Val-Pro-{Nle}-{Hsr}-Ser-NH2

{2-(3-chloro-4-fluorophenoxy)acetic acid}-SAYPDSVP-{Nle}-{Hsr}-S-NH2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bainan Wu, et al. Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells. Chem Biol. 2015 Jul 23;22(7):876-887.  [Content Brief]